Rasonque (daraxonrasib) is an oral RAS inhibitor from Revolution Medicines. RAS is a protein that helps control cell growth. On 15 October 2026 the CHMP recommended a marketing authorisation. The CHMP is the human medicines committee of the European Medicines Agency, the EMA. The recommendation is for adults with metastatic pancreatic adenocarcinoma who have already had at least one systemic therapy. Metastatic means the cancer has spread. A CHMP opinion is not a European Commission decision.
Patients whose disease progresses after first treatment have few options. The options in wide use are chemotherapy. This article is about the opinion, the steps still ahead, and the questions a launch team can ask. It does not treat the medicine as approved in the European Union.
The opinion
The EMA product page says the CHMP adopted a positive opinion for Rasonque as monotherapy in that adult group. The applicant is Revolution Medicines Netherlands B.V. The page says the product will come as 100 mg and 150 mg film-coated tablets. It says treatment should be started by physicians experienced in anticancer medicines.
The opinion was one of six positive opinions on new medicines at the October 2026 CHMP meeting, held from 12 to 15 October. EMA's meeting highlights put the 2026 total so far at 72 positive opinions on new medicines. A positive opinion is a recommendation. It is not the Commission decision that grants the authorisation.
EMA describes daraxonrasib as a RAS inhibitor. In pancreatic adenocarcinoma, mutations in the RAS gene can leave these proteins switched on. EMA says daraxonrasib binds a protein called cyclophilin A, and that pair then attaches to RAS and blocks its signalling. Revolution Medicines describes the molecule as an oral, RAS(ON), multi-selective, noncovalent, tri-complex inhibitor. The company wording is the company's. The mechanism sentence above is EMA's.
Survival figures
The survival figures below come from different readings of the data. The company's hazard ratio is not an EMA result.
EMA reports a phase 3, open-label, multinational study in 500 patients whose metastatic disease had worsened after prior systemic treatment. EMA says 92% had a confirmed RAS G12 mutation. In EMA's summary, median overall survival was 12.4 months with Rasonque against 6.7 months with chemotherapy. Median progression-free survival was 7.2 months against 3.6 months. EMA says the survival analysis used data collected up to 15 June 2026. It says the progression-free survival analysis used data up to 10 February 2026. Those medians are EMA's summary. This page does not average 12.4 with any other survival number.
The company's release is a separate source. It names the trial RASolute 302. It says the primary analysis in the intent-to-treat population showed a hazard ratio for death of 0.40. The company describes that ratio as a 60% reduction in risk. That reading of the hazard ratio is the company's. It is not stated here as an EMA result. The company reports median overall survival of 13.2 months against 6.7 months. It describes the 12.4-month figure as a later ad hoc analysis, generally consistent with the primary one. 12.4 and 13.2 stay in separate sentences.
EMA lists the most common side effects as diarrhoea, rash, stomatitis, nausea and vomiting. Stomatitis is inflammation of the mouth.
US and EU wording
Revolution Medicines says the US Food and Drug Administration approved Rasonque on 26 August 2026. The company says the US indication covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. The CHMP opinion, as EMA publishes it, covers only the group that has already had systemic therapy.
US materials may describe patients outside the CHMP wording. European content should follow the EU product information once the Commission publishes it. Until that text exists, do not treat the US wording as the EU indication.
Patient pool
The company's release, citing published epidemiology, says about 147,000 people are diagnosed with pancreatic cancer in Europe each year. It says five-year survival remains below 10%. It says about 80% of patients are diagnosed after the disease has spread. These are company-cited figures. They are not EMA figures. They describe pancreatic cancer. They do not describe the patients who reach a later line of treatment, who are fit for it, or who are tested for a RAS mutation.
A country forecast needs local inputs the public sources here do not give. Oncologists in each country can describe how many of their patients reach a later line. That is a study. It is not a calculation from the headline.
Pathfinder
EMA launched the Cancer Medicines Pathfinder in 2023 to speed up development and assessment of cancer medicines. One pillar is to identify high-priority products that address an unmet need. EMA says Rasonque was identified as one of those products.
Under the phased review, the CHMP started assessing data months before the complete application was expected. EMA says the review began in early July 2026. The committee evaluated quality, non-clinical and clinical data in stages. EMA says this cut the assessment to less than 150 days. EMA says a standard evaluation can take up to 210 active days, and usually takes around a year once clock stops for company replies are included.
EMA says lessons from this review will inform wider use of phased reviews under new EU pharmaceutical legislation. It says other medicines will be considered case by case. A shorter assessment moves the opinion forward. It does not, by itself, move national pricing. A CHMP opinion is still not a Commission decision.
After the opinion
EMA says the European Commission will fast-track its decision on an EU-wide marketing authorisation. Revolution Medicines notes that, once granted, the authorisation will be valid in all EU member states and in Iceland, Norway and Liechtenstein. It says the authorisation will not cover the United Kingdom or Switzerland. Those sentences describe a future authorisation. They do not say the authorisation has been granted.
Daraxonrasib received EU orphan designation for pancreatic cancer on 20 April 2026. An orphan designation is a status for a medicine aimed at a rare disease. EMA's product page says the agency will review whether the designation can be maintained at authorisation. Orphan market exclusivity is not settled until that review ends.
EMA says that after authorisation, each Member State sets price and reimbursement. That step is national. It has not happened because the Commission decision has not happened.
Joint assessment
Regulation (EU) 2021/2282 created joint clinical assessments. The European Commission describes them as a scientific analysis of the relative effects of a health technology on health outcomes, to support national assessment. Since 12 January 2025, new cancer medicines and advanced therapy medicinal products have been in scope. Orphan medicines join from 13 January 2028. Other medicines covered by the regulation join from 13 January 2030.
EMA says daraxonrasib falls under the HTA Regulation. It says the joint clinical assessment runs independently of the marketing authorisation review. The HTA Secretariat in the European Commission coordinates it. A joint assessment is not the Commission marketing authorisation, and it is not a national price.
The regulation sets the assessment scope as population, intervention, comparators and health outcomes, requested jointly by Member States. It says joint reports should contain no value judgement, because price and budget decisions belong to each country. Member States must give due consideration to a published joint report in their own assessment.
For medicines, the regulation says the draft joint clinical assessment and summary should be endorsed no later than 30 days after the Commission decision that grants a marketing authorisation. The report is timed off a decision that has not yet been taken.
In later-line pancreatic cancer, the regimen in use depends on the first treatment, on fitness and on local practice. A value story built on one comparator may not match what a national body asks. Oncologists in each priority country can say which regimens they use after first-line treatment fails. For the regulation itself, see the guide to the European HTA Regulation. For orphan status, see the EMA orphan drug designation guide.
Centres
National reimbursement, once it exists, is not the same as use in a named hospital. Later-line metastatic pancreatic cancer is usually treated in centres where a small number of physicians see many of the patients. Those centres often run their own drug committee. Two centres in one country can adopt a medicine months apart. Ask which centres treat patients after first-line failure, who sits on the committee, how they sequence treatment now, and what would make them add an oral option. Those are questions. They are not a claim that the Commission has approved the medicine.
The company says Rasonque is a tablet taken once daily. That is the company's statement. In a setting built around infused chemotherapy, a tablet can move dispensing away from the infusion unit. EU product information will be published only after the Commission grants authorisation. The company's dose sentence is not the published EU label.
The company's release quotes US prescribing information. That US text recommends starting skin-protection measures before the first dose, including topical corticosteroids, emollients and sunscreen, and considering oral antibiotics. That is US labelling, quoted by the company. It is not an EMA result, and it is not the EU product information. European protocols are not set until the Commission text exists.
The CHMP indication, as the EMA product page publishes it, does not name a specific RAS mutation. The company says the trial met its primary and key secondary endpoints both in patients with RAS G12 mutations and in the overall population, which included patients with or without an identified tumour RAS mutation. EMA says 92% of trial patients had a confirmed RAS G12 mutation. If clinicians believe a test is required, centres with slow testing may move later, even where the opinion text does not require a test. That is a research question. It is not a label requirement this article adds.
A prescriber study can ask what share of later-line patients a physician would consider, whether the centre already tests RAS status, how the physician reads the survival figures, and which colleagues influence the decision. Keep EMA's 12.4 months and the company's 13.2 months in separate questions. The hazard ratio of 0.40 is the company's reading, not an EMA finding.
Checklist
- Map the regimens used after first-line failure in each priority country. Do not assume one European comparator.
- List high-volume centres and their committee steps before the Commission decision, not after it.
- Test how oncologists read EMA's medians and, separately, the company's hazard ratio and 13.2-month median.
- Ask how centres already support patients on oral cancer medicines. Do not import the US skin regimen as an EU rule.
- Measure current treatment patterns before any national reimbursement. A later wave then has a baseline.
Frequently asked questions
What is Rasonque (daraxonrasib)?
Rasonque (daraxonrasib) is an oral RAS inhibitor from Revolution Medicines. RAS is a protein that helps control cell growth. The CHMP, the European Medicines Agency's human medicines committee, recommended it in October 2026 as monotherapy for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy. A CHMP opinion is not a European Commission decision.
When did the CHMP give its opinion?
The CHMP adopted its positive opinion on 15 October 2026, during its meeting from 12 to 15 October 2026.
Is Rasonque approved in the EU yet?
No. A CHMP opinion is not a Commission decision. The European Commission must issue the marketing authorisation. EMA says the Commission will fast-track that decision. Pricing and reimbursement then happen country by country.
What is the Cancer Medicines Pathfinder?
An EMA project launched in 2023 to speed up the development and assessment of cancer medicines. EMA says it identified Rasonque as a high-priority medicine, which made it eligible for a phased review.
Does Rasonque go through an EU joint clinical assessment?
EMA says daraxonrasib is in scope of the EU HTA Regulation. That regulation has covered new cancer medicines since 12 January 2025. The joint assessment is separate from the Commission decision.
What should launch teams research first?
Which regimens oncologists use after first-line treatment fails, in each priority country, and how high-volume centres decide. Keep the EMA survival figures and the company's hazard ratio in separate sentences. They are not an average.
Plan your European oncology launch research with BioNixus
BioNixus has run primary market research since 2012, with physician, payer and account fieldwork across 48 countries. See healthcare market research in Europe.
If you are preparing a European oncology launch, talk to our team.
This article summarises public regulatory information. It is not medical advice, and it does not promote any medicine. A CHMP opinion is not a Commission decision.
Sources
All accessed 17 October 2026.
- EMA news, "EMA recommends authorisation of Rasonque for metastatic pancreatic cancer", 15 October 2026: https://www.ema.europa.eu/en/news/ema-recommends-authorisation-rasonque-metastatic-pancreatic-cancer
- EMA, Rasonque product page (opinion): https://www.ema.europa.eu/en/medicines/human/EPAR/rasonque
- EMA, "Meeting highlights from the CHMP 12-15 October 2026", 16 October 2026: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026
- EMA, Cancer Medicines Pathfinder: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/cancer-medicines/cancer-medicines-pathfinder
- EMA, orphan designation EU/3/26/3227 (daraxonrasib): https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-26-3227
- European Commission, "Joint clinical assessments for medicinal products": https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/joint-clinical-assessments-medicinal-products_en
- Regulation (EU) 2021/2282 on health technology assessment, EUR-Lex: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32021R2282
- Revolution Medicines press release, 15 October 2026: https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-rasonquetm-daraxonrasib-receives-positive/
- BioNixus, About page: https://www.bionixus.com/about





